Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Tatva Chintan Pharma Chem - Stock

Tatva Chintan Pharma Chem Stock

TATVA.NS
INE0GK401011

Price

1,170.60
Today +/-
+0
Today %
+0 %
P

Tatva Chintan Pharma Chem Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Tatva Chintan Pharma Chem, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Tatva Chintan Pharma Chem from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Tatva Chintan Pharma Chem’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Tatva Chintan Pharma Chem. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Tatva Chintan Pharma Chem’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Tatva Chintan Pharma Chem’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Tatva Chintan Pharma Chem’s growth potential.

Tatva Chintan Pharma Chem Revenue, EBIT and net profit per share

DateTatva Chintan Pharma Chem RevenueTatva Chintan Pharma Chem EBITTatva Chintan Pharma Chem Net Income
2027e7.66 B undefined1.33 B undefined1.01 B undefined
2026e7.89 B undefined1.33 B undefined1.05 B undefined
2025e6.12 B undefined961.76 M undefined777.63 M undefined
20243.94 B undefined425.91 M undefined303.54 M undefined
20234.24 B undefined583.36 M undefined454.87 M undefined
20224.34 B undefined1 B undefined958.74 M undefined
20213 B undefined597.72 M undefined522.62 M undefined
20202.63 B undefined523.87 M undefined377.89 M undefined
20192.06 B undefined315.64 M undefined205.43 M undefined

Tatva Chintan Pharma Chem Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
2019202020212022202320242025e2026e2027e
2.062.6334.344.243.946.127.897.66
-27.5814.1044.39-2.31-7.1155.5028.93-2.89
41.5946.1643.9646.8939.0555.73---
0.861.221.322.031.652.19000
0.320.520.610.580.430.961.331.33
15.2719.8719.8823.0913.7610.8015.7116.8517.36
0.210.380.520.960.450.30.781.051.01
-83.9038.4683.52-52.61-33.26156.4435.52-4.18
---------
---------
22.1722.1722.1721.522.1722.89000
- - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Tatva Chintan Pharma Chem Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Tatva Chintan Pharma Chem is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Tatva Chintan Pharma Chem provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Tatva Chintan Pharma Chem's financial health and stability.

Assets

Tatva Chintan Pharma Chem's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Tatva Chintan Pharma Chem must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Tatva Chintan Pharma Chem after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Tatva Chintan Pharma Chem's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20192020202120222023
0.270.480.611.040.45
4047678195
00000
-276-308-478-937-377
3537017111
3233394284
59829818492
73253196203277
-97-481-209-891-2,031
-167-401-206-1,968-1,011
-0.070.080-1.081.02
00000
210135-4296506
000200
0.170.1-0.052.350.38
-0.04-0.04-0.042.03-0.13
00000
79-49-56585-356
-24.3-228.6-12.74-687.78-1,753.27
00000

Tatva Chintan Pharma Chem stock margins

The Tatva Chintan Pharma Chem margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Tatva Chintan Pharma Chem. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Tatva Chintan Pharma Chem.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Tatva Chintan Pharma Chem's sales revenue. A higher gross margin percentage indicates that the Tatva Chintan Pharma Chem retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Tatva Chintan Pharma Chem's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Tatva Chintan Pharma Chem's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Tatva Chintan Pharma Chem's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Tatva Chintan Pharma Chem. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Tatva Chintan Pharma Chem's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Tatva Chintan Pharma Chem Margin History

Tatva Chintan Pharma Chem Gross marginTatva Chintan Pharma Chem Profit marginTatva Chintan Pharma Chem EBIT marginTatva Chintan Pharma Chem Profit margin
2027e55.74 %17.36 %13.17 %
2026e55.74 %16.85 %13.35 %
2025e55.74 %15.72 %12.71 %
202455.74 %10.82 %7.71 %
202339.05 %13.77 %10.74 %
202246.89 %23.1 %22.11 %
202143.97 %19.9 %17.4 %
202046.16 %19.9 %14.36 %
201941.6 %15.3 %9.96 %

Tatva Chintan Pharma Chem Stock Sales Revenue, EBIT, Earnings per Share

The Tatva Chintan Pharma Chem earnings per share therefore indicates how much revenue Tatva Chintan Pharma Chem has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Tatva Chintan Pharma Chem earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Tatva Chintan Pharma Chem's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Tatva Chintan Pharma Chem’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Tatva Chintan Pharma Chem's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Tatva Chintan Pharma Chem Revenue, EBIT and net profit per share

DateTatva Chintan Pharma Chem Sales per ShareTatva Chintan Pharma Chem EBIT per shareTatva Chintan Pharma Chem Earnings per Share
2027e327.5 undefined0 undefined43.14 undefined
2026e337.25 undefined0 undefined45.04 undefined
2025e261.58 undefined0 undefined33.24 undefined
2024171.9 undefined18.61 undefined13.26 undefined
2023191.12 undefined26.32 undefined20.52 undefined
2022201.7 undefined46.6 undefined44.59 undefined
2021135.51 undefined26.97 undefined23.58 undefined
2020118.76 undefined23.63 undefined17.05 undefined
201993.08 undefined14.24 undefined9.27 undefined

Tatva Chintan Pharma Chem business model

Tatva Chintan Pharma Chem is one of the most popular companies on Eulerpool.com.

Tatva Chintan Pharma Chem valuation based on historical P/E ratio, EBIT, and P/S ratio.

Tatva Chintan Pharma Chem shares outstanding

The number of shares was Tatva Chintan Pharma Chem in 2023 — This indicates how many shares 22.165 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Tatva Chintan Pharma Chem earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Tatva Chintan Pharma Chem's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Tatva Chintan Pharma Chem’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Tatva Chintan Pharma Chem's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Tatva Chintan Pharma Chem Stock Dividend

In 2023, Tatva Chintan Pharma Chem paid a dividend amounting to 2 INR. Dividend means that Tatva Chintan Pharma Chem distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Tatva Chintan Pharma Chem provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Tatva Chintan Pharma Chem’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Tatva Chintan Pharma Chem's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Tatva Chintan Pharma Chem Dividend History

DateTatva Chintan Pharma Chem Dividend
20232 undefined
20222 undefined

Tatva Chintan Pharma Chem Stock Payout Ratio

In 2023, Tatva Chintan Pharma Chem had a payout ratio of 4.48%. The payout ratio indicates the percentage of the company's profits that Tatva Chintan Pharma Chem distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Tatva Chintan Pharma Chem represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Tatva Chintan Pharma Chem could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Tatva Chintan Pharma Chem's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Tatva Chintan Pharma Chem Payout Ratio History

DateTatva Chintan Pharma Chem Payout ratio
2027e4.48 %
2026e4.48 %
2025e4.48 %
20244.48 %
20234.48 %
20224.48 %
20214.48 %
20204.48 %
20194.48 %
Unfortunately, there are currently no price targets and forecasts available for Tatva Chintan Pharma Chem.

Tatva Chintan Pharma Chem Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/20244.28 4.11  (-3.92 %)2024 Q4
12/31/20235.36 1.48  (-72.37 %)2024 Q3
9/30/20235.42 3.43  (-36.77 %)2024 Q2
6/30/20233.81 4.29  (12.57 %)2024 Q1
12/31/20225.87 5.24  (-10.75 %)2023 Q3
1

Eulerpool ESG Scorecard© for the Tatva Chintan Pharma Chem stock

Eulerpool World ESG Rating (EESG©)

36/ 100

🌱 Environment

28

👫 Social

42

🏛️ Governance

40

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Tatva Chintan Pharma Chem Stock Shareholders

%
Name
Stocks
Change
Date
5.92 % Nippon Life India Asset Management Limited1,383,72403/31/2024
3.85 % Patel (Priti Ajay)900,000012/31/2023
3.06 % Patel (Ajay Mansukhlal) HUF715,345012/31/2023
23.07 % Somani (Shekhar Rashiklal)5,396,861012/31/2023
20.94 % Shah (Chintan Nitinkumar)4,897,219012/31/2023
2.78 % SBI Funds Management Pvt. Ltd.650,000012/31/2023
2.15 % ICICI Prudential Asset Management Co. Ltd.503,504-8,98612/31/2023
2.06 % Goldman Sachs Asset Management International481,39739,84412/31/2023
17.10 % Patel (Ajay Mansukhlal)4,000,000012/31/2023
1.91 % Shah (Chintan N) HUF447,500012/31/2023
1
2
3

Tatva Chintan Pharma Chem Executives and Management Board

Mr. Chintan Shah49
Tatva Chintan Pharma Chem Executive Chairman of the Board, Managing Director (since 1996)
Compensation 16.5 M
Mr. Ajaykumar Patel
Tatva Chintan Pharma Chem Whole Time Director (since 1996)
Compensation 16.5 M
Mr. Shekhar Somani
Tatva Chintan Pharma Chem Whole Time Director (since 1996)
Compensation 16.5 M
Mr. Subhash Patel
Tatva Chintan Pharma Chem Non-Executive Independent Director
Compensation 250,000
Dr. Manher Desai
Tatva Chintan Pharma Chem Non-Executive Independent Director
Compensation 230,000
1
2

Tatva Chintan Pharma Chem stock: Frequently Asked Questions

What is the P/E ratio of Tatva Chintan Pharma Chem 2024?

The Tatva Chintan Pharma Chem P/E ratio is 88.28.

What is the P/S ratio of Tatva Chintan Pharma Chem 2024?

The Tatva Chintan Pharma Chem P/S ratio is 6.81.

What is the AlleAktien quality score of Tatva Chintan Pharma Chem?

The AlleAktien quality score for Tatva Chintan Pharma Chem is 3/10.

What is the revenue of Tatva Chintan Pharma Chem 2024?

The Tatva Chintan Pharma Chem revenue is 3.94 B INR.

How high is the profit of Tatva Chintan Pharma Chem 2024?

The Tatva Chintan Pharma Chem profit is 303.54 M INR.

What is the business model of Tatva Chintan Pharma Chem

No history available for Tatva Chintan Pharma Chem.

What is the Tatva Chintan Pharma Chem dividend?

Tatva Chintan Pharma Chem pays a dividend of 2 INR distributed over payouts per year.

How often does Tatva Chintan Pharma Chem pay dividends?

The dividend cannot currently be calculated for Tatva Chintan Pharma Chem or the company does not pay out a dividend.

What is the Tatva Chintan Pharma Chem ISIN?

The ISIN of Tatva Chintan Pharma Chem is INE0GK401011.

What is the Tatva Chintan Pharma Chem ticker?

The ticker of Tatva Chintan Pharma Chem is TATVA.NS.

How much dividend does Tatva Chintan Pharma Chem pay?

Over the past 12 months, Tatva Chintan Pharma Chem paid a dividend of 2 INR . This corresponds to a dividend yield of about 0.17 %. For the coming 12 months, Tatva Chintan Pharma Chem is expected to pay a dividend of 2 INR.

What is the dividend yield of Tatva Chintan Pharma Chem?

The current dividend yield of Tatva Chintan Pharma Chem is 0.17 %.

When does Tatva Chintan Pharma Chem pay dividends?

Tatva Chintan Pharma Chem pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Tatva Chintan Pharma Chem?

Tatva Chintan Pharma Chem paid dividends every year for the past 3 years.

What is the dividend of Tatva Chintan Pharma Chem?

For the upcoming 12 months, dividends amounting to 2 INR are expected. This corresponds to a dividend yield of 0.17 %.

In which sector is Tatva Chintan Pharma Chem located?

Tatva Chintan Pharma Chem is assigned to the 'Commodities' sector.

Wann musste ich die Aktien von Tatva Chintan Pharma Chem kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tatva Chintan Pharma Chem from 9/29/2023 amounting to 2 INR, you needed to have the stock in your portfolio before the ex-date on 9/8/2023.

When did Tatva Chintan Pharma Chem pay the last dividend?

The last dividend was paid out on 9/29/2023.

What was the dividend of Tatva Chintan Pharma Chem in the year 2023?

In the year 2023, Tatva Chintan Pharma Chem distributed 2 INR as dividends.

In which currency does Tatva Chintan Pharma Chem pay out the dividend?

The dividends of Tatva Chintan Pharma Chem are distributed in INR.

Other fundamentals and analyses of Tatva Chintan Pharma Chem in the deep dive.

Our stock analysis for Tatva Chintan Pharma Chem Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tatva Chintan Pharma Chem Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.